Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dorzolamide-timolol for Anti-VEGF Non-Responders in Wet AMD
NCT02571972Phase 2Completed
- Sponsor
- Wills Eye Hospital
- Start
- Feb 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dorzolamide + timolol in exudative macular degeneration, sponsored by Wills Eye Hospital. Started Feb 2015; status: completed.
02
Drugs
dorzolamide + timolol
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT02571972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571972.